EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Neurobeachin ( NBEA ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss

Arshiya Mariam-Smith iD, Joseph H Breeyear, Noah J Daniels, Kevin M Pantalone iD, Marcio L Griebeler, Alison A Motsinger-Reif, Daniel M Rotroff iD

Diabetes, Obesity and Metabolism · 2025-10 · 27 (10) · 5632-5642

DOI: 10.1111/dom.16612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 18.07.2025. Verfasst von Arshiya Mariam-Smith und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Nerve Tissue Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, Center for Quantitative Metabolic Research, Cleveland Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Nearly 42% of adults in the United States have obesity, a significant risk factor for many cardiometabolic diseases and cancers. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are promising interventions for weight loss, but their efficacy varies significantly across individuals. This study investigates the role of neurobeachin ( NBEA ), a gene that encodes a protein kinase A anchor protein, on weight loss response in two large, real‐world cohorts. Materials and Methods We utilised data from individuals prescribed a GLP‐1RA in the NIH All of Us ( N = 6556) and validated in the UK Biobank ( N = 241). The NBEA genetic score for weight loss (12–18 months) was developed using the NIH All of Us cohort and independently validated in the UK Biobank. Logistic regression modelled associations between the score and outcomes, including high responsiveness (top 20th percentile for weight loss) and non‐responsiveness (weight change ≥0%).

Results

Individuals meeting the responsive NBEA score threshold were 82% more likely to be highly responsive (FDR p = 1·8 × 10 −6 ) on liraglutide and were validated in the UK Biobank (odds ratio (OR) = 2·37; p = ·008). Individuals on semaglutide meeting this threshold for highly responsive had OR = 1·63 and OR = 2·21 in discovery and validation sets respectively ( p < ·05). Individuals on liraglutide with a non‐responsive NBEA score were 50% more likely to not lose weight (FDR p = 2.9 × 10 −4 ) and were validated in the UK Biobank (OR = 1·81; p = ·041), but the non‐response score did not validate for semaglutide.

Conclusion

These findings indicate that NBEA genetic variation is predictive of GLP‐1RA weight loss and may support future efforts to identify individuals likely to experience significant weight loss with GLP‐1RAs, enabling personalised obesity treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossGlucagon-Like Peptide-1 Receptor AgonistsObesityNerve Tissue ProteinsAdaptor Proteins, Signal TransducingHumansMaleFemaleMiddle AgedAgedAdultUnited KingdomCohort StudiesLiraglutide

Stichwörter der Autor:innen

GLP‐1RANBEAelectronic health recordsgenetic scoreweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsNerve Tissue ProteinsAdaptor Proteins, Signal TransducingLiraglutide

Autor:innen und Institutionen

  • Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Center for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, Ohio, USA.
  • Biostatistics and Computational Biology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
  • Department of Endocrinology, Medical Specialty Institute, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Arshiya Mariam-Smith, Kevin M Pantalone, Daniel M Rotroff

Förderung

  • NHLBI NIH HHS
  • Center for Quantitative Metabolic Research, Cleveland Clinic

Zitieren

APA

Mariam-Smith, A., Breeyear, J. H., Daniels, N. J., Pantalone, K. M., Griebeler, M. L., Motsinger-Reif, A. A., & Rotroff, D. M. (2025). Neurobeachin ( NBEA ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss. Diabetes, Obesity and Metabolism, 27(10), 5632-5642. https://doi.org/10.1111/dom.16612

Vancouver

Mariam-Smith A, Breeyear JH, Daniels NJ, Pantalone KM, Griebeler ML, Motsinger-Reif AA, et al. Neurobeachin ( NBEA ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss. Diabetes, Obesity and Metabolism. 2025;27(10):5632-5642. doi:10.1111/dom.16612

BibTeX
@article{MariamSmith2025,
  author = {Mariam-Smith, Arshiya and Breeyear, Joseph H and Daniels, Noah J and Pantalone, Kevin M and Griebeler, Marcio L and Motsinger-Reif, Alison A and Rotroff, Daniel M},
  title = {Neurobeachin ( NBEA ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {10},
  pages = {5632--5642},
  doi = {10.1111/dom.16612}
}
Kostenlos starten →